Loading
Active Biomarkers is strengthening its Flow Cytometry capabilities with Novocyte Quanteon (Agilent) technology for faster immune system analysis.
- 20 color configuration
- save precious samples & time
- sophisticated and comprehensive multi-parameter analyses
We are proud to announce our recently disclosed EXCELLENT grades at the 2020 EQAPOL evaluations of ELISpot and Luminex assays.
These two grades emphasize the commitment to high-quality standards from the whole ACTIVE Team for both cell-based methods and immunoassays.
When it comes to assay development, matching short timelines, reliable assay performances, and cost-effectiveness is always a challenge.
In our effort to actively provide you with the best solutions for PK, ADAs, or Biomarker monitoring, we recently completed our technological platform with the Gyros XPlore technology.
Following its acquisition by its senior management and Turenne Santé Group, ABL Lyon has changed its name and logo, to become Active Biomarkers (see Press Release).
But our team, our spirit and our vision remain the same: transforming unique biological samples into actionable information, with a strong sense of commitment!
This important milestone would not have been possible without the continued trust of our clients. We are proud to support them in the development of future life-changing therapies to fight cancer, infectious pathogens, neurodegenerative disorders or inflammatory diseases.
Summertime is not over yet...!
Choose or Design your Perfect Cocktail of Biomarkers
Whether in infectious diseases (COVID-19, Sepsis, Zika), immuno-oncology, auto-immune, inflammatory disorders, evaluating innovative immunotherapies (ICPI) or cell therapies (CAR-T cells), uncontrolled release of cytokines, known as cytokine storm, may be life-threatening for patients. Detecting harmful levels of cytokines is a matter of life or death for patients, and crucial for adapting patient care.
As an expert in soluble biomarker analysis, ABL is a partner of choice to support you overcome these challenges.